Lexaria DehydraTECH(TM) 2.0 Outperforms MCT in 2021 R&D Study


New York, New York–(Newsfile Corp. – May 25, 2021) – PCG Digital — The positive results keep rolling in for Lexaria (LEXX). They recently released R&D study results for three new DehydraTECHTM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard.

Though new to NASDAQ, Lexaria Bioscience Corp. has been producing positive test results with their patented DehydraTECHTM bio-absorption technology since 2016. The process has been used in foods, beverages, oral supplements, tablets, and capsules.

The first iteration of the technology – “Original” DehydraTECH – increased absorption rates of cannabinoids and nicotine by up to 390%. In 2019, newer versions – DehydraTECHTM 2.0 – tested as high as 923% above industry standards. But now, test results from May of 2021 showed a CBD delivery rate that was up to 2,708% stronger than medium chain triglyceride (MCT) oils which have become industry standard.

Over the past few years, the CBD industry has been using coconut and/or other MCT oils as the most common way to deliver oral cannabinoids, primarily because they taste good. These recent study results may change a few minds about that. Lexaria has been proving their science is effective for half a decade now.

Strategic Initiatives for 2021 Show a Diverse Use Scenario for DehydraTECHTM

A revolutionary technology like DehydraTECHTM has a wide range of uses that goes beyond consumer CBD use. In November of 2020, Lexaria published a list of 2021 strategic initiatives that also targets hypertension treatment, nicotine delivery, and antiviral absorption.

The anti-hypertension drug market is estimated at over $30 billion. In 2021, DehydraTECHTM CBD is part of three human clinical studies (already started and fully funded) on the effects of CBD as a hypertension treatment option. The first study conducted in 2018 produced evidence of a 5% drop in blood pressure after a single 90mg dose.

On the nicotine front, Lexaria has issued a technology license to Altria Ventures Inc. and is in the midst of a formal R&D agreement with British American Tobacco, two of the five largest nicotine companies in the world. Early studies on DehydraTECHTM nicotine oral pouches show nicotine effectiveness in 1.5-4 minutes.

Viral diseases like HIV, Influenza, Ebola, and now COVID-19, have killed millions in just the past few years. With the higher absorption rate of DehydraTECHTM, antiviral drugs for these diseases, currently administered by injection, could potentially be delivered orally.

Lexaria Expands into India with New Patent Approval

Adding to its already impressive collection of patents in the US, EU, and Australia, Lexaria was just approved for a new patent in India for “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” It’s the 19th patent they’ve been granted.

The new patent covers a broad range of ingredients, including NSAIDS, nicotine, and cannabinoids. As the title suggests, it’s a beverage patent, but the allowed product formats cover everything from carbonated sodas to fruit juices, coffee and energy drinks, and oral medicines.

CBD-infused beverages, though not the most lucrative offering from Lexaria, are part of the $23.6 billion consumer CBD market. An established position in that sector has helped the company grow in other areas that could be worth significantly more to them going forward.

Licensing and White Label Opportunities for Prospective Partners

Lexaria is a biopharmaceutical company, not a retail chain store. Other companies license the technology to empower their own retail brands which are currently available in thousands of locations across the US. The company’s main goal is to increase the use of DehydraTECHTM through strategic partnerships. That includes drug companies and consumer packaged goods.

The absorption rate achieved in clinical studies is due to the ability that DehydraTECHTM has shown in delivering fat-soluble molecules through the gastrointestinal system by piggy-backing and improving upon known, natural human absorptive processes. It’s also been shown effective in transdermal applications, giving it even broader potential for topical use.

Companies with existing drugs, oral supplements, beverages, and pills can license this technology and effectively increase the potency and effectiveness of their product. Lexaria is working with several partners now who are doing this.

As an investment, Lexaria (LEXX) is up 27.14% in the past thirty days. The iShares NASDAQ Biotechnology ETF (IBB) is down 2.88% over that period. Nasdaq (NDAQ) itself only gained 3.35%, so Lexaria definitely “beat the market.” That’s a good sign for partners and investors.


This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG may be compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.

Contact: info@pcgadvisory.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84962